Antibody-Drug Conjugates (ADCs) Products

Antibody-drug conjugates (ADCs) are a new class of highly potent biopharmaceutical drugs designed as a targeted therapy for the treatment of patients with cancers. Typically, an ADC is composed of three core elements, the monoclonal antibody, the linker and the cytotoxic agent. In developing ADCs, an anticancer drug is coupled to an antibody that specifically targets a certain tumor marker (e.g. a protein that, ideally, is only to be found in or on tumor cells). Antibodies track these proteins down in the body and attach themselves to the surface of cancer cells. The biochemical reaction between the antibody and the target protein (antigen) triggers a signal in the tumor cell, which then absorbs or internalizes the antibody together with the cytotoxin. After the ADC is internalized, the cytotoxic drug is released and kills the cancer. Typical examples are Brentuximab vedotin (SGN35), Trastuzumab-emtansine (T-DM1), Inotuzumab ozogamicin (CMC-544) and Gemtuzumab ozogamicin.

Creative Biolabs' scientists are focusing on applying excellent science and technology to discover and develop potential new ADCs with the goal of becoming first-in-class therapeutics. We also provide custom ADCs design and construction services. Besides expression and purification of ADCs, we also provide pharmacokinetics studies, HPLC/ELISA/TFC-MS/MS analysis for free drug and pharmacokinetics analysis.

ADC Name Cytotoxin Linker MAb Target
ABT-414-VC-MMAE Auristatin MMAE Valine–citrulline ABT-414 EGFR
AGS-16M8F-VC-MMAE Auristatin MMAF Valine–citrulline AGS-16M8F AGS-16
AMG-172-SMCC-DM1 Maytansine DM1 SMCC AMG-172 CD70 (CD27L)
AMG-595-SMCC-DM1 Maytansine DM1 SMCC AMG-595 EGFRviii
ARX788 Amberstatin (AS269) Valine–citrulline ARX788 HER2
ASG-15ME-VC-MMAE Auristatin MMAE Valine–citrulline ASG-15ME SLTRK6
ASG-22CE-VC-MMAE Auristatin MMAE Valine–citrulline ASG-22CE Nectin 4
ASG-22ME-VC-MMAE Auristatin MMAE Valine–citrulline ASG-22ME Nectin 4
ASG-5ME-VC-MMAE Auristatin MMAE Valine–citrulline ASG-5ME SLC44A4 (AGS-5)
BAY-79-4620-VC-MMAE Auristatin MMAE Valine–citrulline BAY-79-4620 CA-IX
BAY-94-9343-SPDB-DM4 Maytansine DM4 SPDB BAY-94-9343 Mesothelin
Brentuximab-VC-MMAE Auristatin MMAE Valine-citrulline Brentuximab vedotin (SGN35) CD30
BT-062-SPP-DM4 Maytansine DM4 SPP BT-062 CD138
Coltuximab-SPDB-DM4 Maytansine DM4 SPDB Coltuximab Ravtansine (SAR-3419) CD19
EC-mAb-Maleimidocaproyl Phenylalanine-PBD dimer Pyrrolobenzodiazepine (PBD) dimer Maleimidocaproyl Phenylalanine SGN- CD33A (EC-mAb) CD22
Epratuzumab–Lysine-SN38 Irinotecan metabolite (SN38) Lysine Epratuzumab–SN-38 CD33 and CD22
Gemtuzumab-Hydrazone-N-acetyl- γ Calicheamicin N-acetyl- γ Calicheamicin Hydrazone Gemtuzumab ozogamicin GPNMB (Glycoprotein NMB)
Glembatumumab-VC-MMAE Auristatin MMAE Valine–citrulline Glembatumumab vedotin (CDX-011) Tissue Factor (TF)
HuMax-TF-VC-MMAE Auristatin MMAE Valine–citrulline HuMax-TF-ADC CD37
IMGN-529-SPDB-DM4 Maytansine DM4 SPDB IMGN-529 Folate receptor 1
IMGN-853-Lysine-SN38 Irinotecan metabolite (SN38) Lysine IMGN-853 TACSTD2 / TROP2 or EGP1
Inotuzumab-Hydrazone-N-acetyl- γ Calicheamicin N-acetyl- γ Calicheamicin Hydrazone (4-(4-acetylphenoxy)butanoic acid) Inotuzumab ozogamicin (CMC-544) CEA-CAM4/CD66e
Labetuzumab-Carbonate-SN38 Irinotecan metabolite (SN38) Carbonate Labetuzumab-SN-38 (IMMU-130) CD56
Lorvotuzumab-N-succinimidyl-4-(2-pyridyldithio)butyrate-DM1 Maytansine DM1 (N-succinimidyl-4-(2-pyridyldithio)butyrate) Lorvotuzumab mertansine (IMGN-901) CD70 (TNFSF7)
MDX-1203-Di-peptide-Duocarmycin Duocarmycin (DNA damage) Di-peptide MDX-1203 STEAP1
Milatuzumab doxorubicin (IMMU-110) Doxorubicin Hydrazone Milatuzumab doxorubicin (IMMU-110) Mucin 16
MLN-0264-VC-MMAE Auristatin MMAE Valine–citrulline MLN-0264 CD79b
PF-0626350-VC-MMAE Auristatin MMAE Valine–citrulline PF-0626350
Pinatuzumab-VC-MMAE Auristatin MMAE Valine–citrulline Pinatuzumab vedotin (RG-7593 / DCDT 2980S) NaPi2b
RG-7450-VC-MMAE Auristatin MMAE Valine–citrulline RG-7450 / DSTP 3086 S Endothelin receptor ETB
RG-7458-SMCC-DM1 Maytansine DM1 SMCC RG-7458 / DMUC 5754 A CA6
RG-7596-VC-MMAE Auristatin MMAE Valine–citrulline RG-7596 / DCDS4501A
RG-7599-VC-MMAE Auristatin MMAE Valine–citrulline RG-7599 / DNIB 0600 A CD70
RG-7600-VC-MMAE Auristatin MMAE Valine–citrulline RG-7600 CD70
RG-7636-VC-MMAE Auristatin MMAE Valine–citrulline RG-7636 CD19
SAR-566658-SPDB-DM4 Maytansine DM4 SPDB SAR-566658 LIV1
SC16LD6.5-Di-peptide-DNA damaging agent DNA damaging agent Di-peptide SC16LD6.5 HER2
SGN-75-VC-MMAE Auristatin MMAF Valine–citrulline SGN-75 CD70
SGN-CD19A-VC-MMAE Auristatin MMAE Valine–citrulline SGN-CD19A
SGN-LIV1-A-VC-MMAE Auristatin MMAE Valine–citrulline SGN-LIV1-A
SGN-Maleimidocaproyl Phenylalanine-PBD dimer Pyrrolobenzodiazepine (PBD) dimer Maleimidocaproyl Phenylalanine SGN CD70 A
Trastuzumab-SMCC-DM1 Maytansine DM1 SMCC Trastuzumab-emtansine (T-DM1)
Vorsetuzumab-VC-MMAE Auristatin MMAF Valine–citrulline Vorsetuzumab mafodotin

All listed customized services & products are for research use only, not intended for pharmaceutical, diagnostic, therapeutic or any in vivo human use.

Online Inquiry

Verification code
Click image to refresh the verification code.


USA: 45-1 Ramsey Road, Shirley, NY 11967, USA
Europe: UK - Germany
Call us at:
USA: 1-631-381-2994
Fax: 1-631-207-8356
Our customer service representatives are available 24 hours a day, 7 days a week. Contact Us